CDC (Centers for Disease Control and Prevention). 1967–1971. Application and Report on Manufacture of Anthrax Protective Antigen, Aluminum Hydroxide Adsorbed (DBS-IND 180). Observational Study. Atlanta, Ga.: Centers for Disease Control and Prevention.


Donlon JA. 1993. FDA approval of Michigan Department of Public Health ammendment to establishment license application. Letter to Myers RC, Michigan Department of Public Health, Lansing, Mich.


Elengold, M, Deputy Director, Operations, Center for Biologics Evaluation and Research, FDA. 2000. Anthrax Vaccine Immunization Program—What Have We Learned? Statement at the October 3, 2000, hearing of the Committee on Government Reform, U.S. House of Representatives, Washington, D.C.

Elengold M. 2001. Technical review. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., December 12.


FDA (Food and Drug Administration). 1985. Biological products: bacterial vaccines and toxoids: implementation of efficacy review. Proposed rule. Federal Register 50(240): 51002–51117.

FDA. 1987. Guideline on General Principles of Process Validation. Rockville, Md.: Food and Drug Administration.

FDA. 1993. Form FDA 483 issued to Michigan Department of Public Health. Period of inspection: January 14–15, 1993. Letter to Myers R, Michigan Department of Public Health, Lansing, Mich.

FDA. 1998a. Form FDA 483 issued to Michigan Biologic Products Institute. Period of inspection: February 4–20, 1998. Letter to Myers RC, Michigan Biologic Products Institute, Lansing, Mich.

FDA. 1998b. Form FDA 483 issued to BioPort Corporation. Period of inspection: October 19–23, 1998. Letter to El-Hibri F, BioPort Corporation, Lansing, Mich.

FDA. 1999a. Establishment Inspection Report of BioPort Corporation, October 19–23, 1998. Rockville, Md.: FDA.

FDA. 1999b. Form FDA 483 issued to BioPort Corporation. Period of inspection: November 15–23, 1999. Letter to El-Hibri F, BioPort Corporation, Lansing, Mich.

FDA. 2000. Form FDA 483 issued to BioPort Corporation. Period of inspection: October 10–26, 2000. Letter to Kramer RG, BioPort Corporation, Lansing, Mich.

FDA. 2001a. Form FDA 483 issued to BioPort Corporation. Period of inspection: December 12–19, 2000. Letter to Kramer RG, BioPort Corporation, Lansing, Mich.

FDA. 2001b (December 19). Press Release: Pre-approval Inspection of the BioPort Facility. Rockville, Md.: FDA.

Feeley JC, Manclark CR, O’Malley JP, Kolb RW. 1969. Michigan Department of Public Health anthrax vaccine, evaluation of clinical data submitted under IND-180 on January 22, 1969. Memorandum to Pittman M, U.S. Department of Health, Education, and Welfare, Washington, D.C.


GAO (General Accounting Office). 2001. Anthrax Vaccine: Changes to the Manufacturing Process. GAO-02-181T. Washington, DC: GAO.

Goldenthal K. 2002. The labeling supplement to your license application for Anthrax Vaccine Adsorbed has been approved. Letter to Giri L, BioPort Corporation, Lansing, Mich.

Giri L, Kramer R, Myers R, Brennan-Root K, Waytes T, Winberry L. 2001. BioPort response to committee questions. Presentation to the Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Meeting IV, Washington, D.C.


Masiello SA. 2001. FDA approval of a BioPort Corporation biologics license application supplement. Letter to Giri L, BioPort Corporation, Lansing, Mich.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement